Dupixent Improves Symptoms and Reduces Inflammatory Cells in Esophageal Disorder

Sanofi and Regeneron added another brick to their joint Dupixent franchise with more phase 3 data confirming the antibody’s benefit in eosinophilic esophagitis, a chronic inflammatory disorder that can increase the risk of esophageal cancer.
Source: Drug Industry Daily